NasdaqGM:ZLABBiotechs
Is Zai Lab’s (ZLAB) Rising Losses for Pipeline Expansion Strengthening or Straining Its Investment Case?
In the second quarter of 2026, Zai Lab Limited reported revenue of US$106.31 million, down from US$109.98 million a year earlier, with net loss widening to US$50.83 million and basic loss per share from continuing operations rising to US$0.50 from US$0.40.
Over the first half of 2026, revenue slipped to US$205.92 million while net loss increased to US$101.84 million, highlighting that the company’s push to build its pipeline and commercial footprint is still weighing on profitability.
We’ll...